Hospital
University of California Irvine
University of California Irvine was paid $21.51M by Medicaid between Jan 2018 and Dec 2024, across 195 billing codes. Its largest line is 0450, Emergency room services — 26% of everything it billed.
33Billing provider infoUNIVERSITY OF CALIFORNIA IRVINE
LAKEWOOD, CA 90712
LAKEWOOD, CA 90712
33aNPI1184655581assigned 07/05/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$21.51M
24GClaims687,655
24DCodes billed195
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#116 of 410
Median peer was paid$6.90M
This provider vs. median3.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 128,721 | $2.89M | |
| 2019 | 119,734 | $3.91M | |
| 2020 | 84,292 | $2.76M | |
| 2021 | 86,631 | $3.13M | |
| 2022 | 93,393 | $3.93M | |
| 2023 | 109,586 | $3.47M | |
| 2024incomplete | 65,298 | $1.42M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 26% | 83,503 | 75,084 | $5.49M |
| 70450 | Computed tomography, head or brain; without contrast material | 5.6% | 8,319 | 7,996 | $1.21M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.6% | 4,752 | 4,549 | $979K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.8% | 29,264 | 26,685 | $810K |
| 80053 | Comprehensive metabolic panel | 3.7% | 29,637 | 27,438 | $797K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.8% | 2,639 | 2,484 | $600K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.8% | 46,609 | 42,041 | $599K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 13,689 | 12,526 | $575K |
| 99199 | Unlisted special service, procedure or report | 2.2% | 6,336 | 5,732 | $464K |
| 93970 | 2.1% | 2,966 | 2,855 | $449K | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.0% | 3,649 | 3,444 | $422K |
| 71045 | Radiologic examination, chest; single view | 1.8% | 21,859 | 20,543 | $395K |
183 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 3,261 | $372K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 11,733 | $359K |
| 84484 | 1.7% | 20,679 | $358K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.6% | 15,965 | $339K |
| Z7502 | 1.6% | 8,608 | $334K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.5% | 5,258 | $332K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 4,567 | $321K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 4,834 | $317K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.5% | 4,221 | $314K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 4,587 | $246K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.1% | 5,822 | $242K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 10,603 | $240K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.1% | 1,122 | $230K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 10,627 | $216K |
| 99283 | Emergency room visit (moderate) | <1% | 2,510 | $209K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,318 | $193K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,559 | $158K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,034 | $151K |
| J3490 | Unclassified drugs | <1% | 15,061 | $148K |
| 83880 | <1% | 5,051 | $145K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,033 | $144K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,170 | $134K |
| 83690 | <1% | 15,184 | $122K | |
| 81001 | <1% | 19,112 | $121K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,915 | $120K |
| 76830 | Ultrasound, transvaginal | <1% | 2,012 | $117K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 394 | $109K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,614 | $106K |
| 87040 | <1% | 4,015 | $102K | |
| 87400 | <1% | 6,583 | $88K | |
| 76801 | <1% | 1,578 | $82K | |
| 0360 | <1% | 1,748 | $73K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,475 | $71K |
| 81025 | <1% | 12,197 | $71K | |
| 73564 | <1% | 2,533 | $71K | |
| 84703 | <1% | 5,170 | $69K | |
| 72100 | <1% | 2,030 | $67K | |
| 0270 | <1% | 8,031 | $65K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,666 | $59K |
| 0250 | <1% | 1,277 | $58K | |
| 76770 | <1% | 834 | $54K | |
| 0272 | <1% | 8,690 | $53K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 10,447 | $52K |
| 83605 | <1% | 4,216 | $52K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,889 | $50K |
| 85610 | <1% | 6,454 | $48K | |
| 73030 | <1% | 1,880 | $47K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 874 | $47K |
| 73610 | <1% | 1,693 | $47K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,428 | $47K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,628 | $46K |
| 80076 | <1% | 3,962 | $45K | |
| 73630 | <1% | 1,937 | $45K | |
| 94664 | <1% | 2,879 | $44K | |
| 90715 | <1% | 1,309 | $39K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,799 | $38K |
| 73130 | <1% | 1,515 | $37K | |
| 85730 | <1% | 4,223 | $36K | |
| 87186 | <1% | 2,745 | $36K | |
| 87077 | <1% | 2,774 | $35K | |
| 80047 | <1% | 2,226 | $35K | |
| 83735 | <1% | 3,159 | $32K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 604 | $29K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 73 | $29K |
| 0710 | <1% | 2,420 | $25K | |
| 87430 | <1% | 3,008 | $23K | |
| 96376 | <1% | 1,464 | $23K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,619 | $23K |
| 84702 | <1% | 1,872 | $22K | |
| 72040 | <1% | 817 | $21K | |
| 82962 | <1% | 5,041 | $21K | |
| 85379 | <1% | 1,866 | $21K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,785 | $20K |
| 70486 | <1% | 136 | $18K | |
| 73502 | <1% | 416 | $16K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,696 | $16K |
| 81003 | <1% | 5,447 | $15K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,097 | $14K |
| 73110 | <1% | 510 | $14K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,321 | $14K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,964 | $13K |
| 86901 | <1% | 2,354 | $13K | |
| 86900 | <1% | 2,355 | $12K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,217 | $11K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,137 | $11K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,353 | $10K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 575 | $9K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,208 | $9K |
| 0762 | <1% | 266 | $9K | |
| 87420 | <1% | 1,147 | $8K | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 245 | $8K |
| 0300 | <1% | 222 | $8K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 748 | $7K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 944 | $7K |
| 84100 | <1% | 1,202 | $7K | |
| 0750 | <1% | 300 | $6K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 601 | $6K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,183 | $6K |
| 86850 | <1% | 660 | $6K | |
| 96367 | <1% | 153 | $6K | |
| 73590 | <1% | 241 | $6K | |
| 87070 | <1% | 474 | $5K | |
| 0160 | <1% | 107 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,706 | $5K |
| 93976 | <1% | 48 | $5K | |
| 85027 | <1% | 1,151 | $5K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 334 | $5K |
| Z7610 | <1% | 350 | $5K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 751 | $5K |
| A4217 | Sterile water/saline, 500 ml | <1% | 719 | $4K |
| 93017 | <1% | 98 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,086 | $4K |
| 73140 | <1% | 229 | $4K | |
| A9150 | Non-prescription drugs | <1% | 1,933 | $4K |
| 82550 | <1% | 546 | $4K | |
| 87210 | <1% | 908 | $4K | |
| 0320 | <1% | 241 | $3K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 283 | $3K |
| 73080 | <1% | 167 | $3K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 525 | $3K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 41 | $3K |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 55 | $3K |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 14 | $3K |
| A9270 | Non-covered item or service | <1% | 1,557 | $3K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 207 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 97 | $2K |
| 76870 | <1% | 52 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 217 | $2K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 29 | $2K |
| 72072 | <1% | 68 | $2K | |
| 29125 | <1% | 182 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 299 | $2K |
| 93971 | <1% | 29 | $2K | |
| 84145 | <1% | 110 | $2K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 77 | $2K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 25 | $2K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 14 | $1K |
| 0011A | <1% | 34 | $1K | |
| 71020 | <1% | 52 | $1K | |
| 71010 | <1% | 72 | $1K | |
| 94644 | <1% | 29 | $1K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 201 | $1K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 24 | $974.83 |
| 74018 | <1% | 47 | $889.15 | |
| 0258 | <1% | 43 | $828.73 | |
| 73090 | <1% | 61 | $782.10 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 85 | $685.44 |
| 71100 | <1% | 38 | $652.76 | |
| 0012A | <1% | 16 | $640.00 | |
| 99070 | <1% | 494 | $563.86 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 30 | $539.48 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 13 | $538.97 |
| 86140 | <1% | 96 | $477.95 | |
| 88312 | <1% | 192 | $425.79 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 67 | $404.85 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 15 | $371.23 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 54 | $362.62 |
| 82805 | <1% | 13 | $235.62 | |
| 82140 | <1% | 29 | $234.19 | |
| 86308 | <1% | 58 | $222.38 | |
| 29515 | <1% | 29 | $211.70 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 61 | $191.80 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 16 | $151.56 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 17 | $146.95 |
| 12001 | <1% | 16 | $144.64 | |
| A4649 | Surgical supply; miscellaneous | <1% | 293 | $134.89 |
| 94760 | <1% | 26 | $129.32 | |
| 84439 | <1% | 14 | $106.85 | |
| 80061 | Lipid panel | <1% | 13 | $99.15 |
| J1815 | Injection, insulin, per 5 units | <1% | 45 | $84.57 |
| 83615 | <1% | 13 | $81.71 | |
| 0760 | <1% | 12 | $65.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 12 | $60.50 |
| 10060 | <1% | 12 | $60.00 | |
| 85651 | <1% | 14 | $48.43 | |
| 85014 | <1% | 27 | $30.00 | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 26 | $30.00 |
| 84550 | <1% | 13 | $28.09 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 88 | $24.45 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 14 | $16.30 |
| 0730 | 0% | 14 | $0.00 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 65 | $0.00 |
| 0370 | 0% | 116 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSIWABESSY, RANDOLPH (VICE PRESIDENT AND CHIEF FINANCIAL)
Parent organizationUNIVERSITY OF CALIFORNIA IRVI
| Provider | Location | Paid |
|---|---|---|
| University of California Irvine | Orange, CA | $153.06M |
| University of California Irvine | Fountain Valley, CA | $16.83M |
| University of California Irvine | Placentia, CA | $6.87M |
| University of California Irvine | Los Alamitos, CA | $6.02M |
| Uc Regents | Fountain Valley, CA | $39K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.